Do analysts prefer AQB or AKTX?

Akari Therapeutics has a consensus target price of $32.33, suggesting a potential upside of 268.68%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akari Therapeutics is more favorable than AquaBounty Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AquaBounty Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Akari Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has preferable earnings and valuation, AQB or AKTX?

Akari Therapeutics has lower revenue, but higher earnings than AquaBounty Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AquaBounty Technologies $2.47M 2.19 -$18.49M -$0.82 N/A Akari Therapeutics N/A N/A -$17.30M N/A N/A

Is AQB or AKTX more profitable?

AquaBounty Technologies' return on equity of -147.07% beat Akari Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets AquaBounty Technologies N/A -147.07% -28.73% Akari Therapeutics N/A -147.45% -74.70%

Do analysts rate ESLA or AQB?

Estrella Immunopharma presently has a consensus price target of $8.00, indicating a potential upside of 1,851.22%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than AquaBounty Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 AquaBounty Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ESLA or AQB more profitable?

Estrella Immunopharma's return on equity of 0.00% beat AquaBounty Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -328.72% AquaBounty Technologies N/A -147.07% -28.73%

Is MRKR or AQB more profitable?

Marker Therapeutics' return on equity of -56.96% beat AquaBounty Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Marker Therapeutics N/A -56.96% -47.82% AquaBounty Technologies N/A -147.07% -28.73%

Do analysts prefer AQB or DYAI?

Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 575.52%. Given Dyadic International's stronger consensus rating and higher probable upside, analysts plainly believe Dyadic International is more favorable than AquaBounty Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AquaBounty Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dyadic International 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate AQB or NXTC?

NextCure has a consensus price target of $19.00, suggesting a potential upside of 164.62%. Given NextCure's stronger consensus rating and higher probable upside, analysts clearly believe NextCure is more favorable than AquaBounty Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AquaBounty Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NextCure 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is AQB or NXTC more profitable?

AquaBounty Technologies' return on equity of -147.07% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets AquaBounty Technologies N/A -147.07% -28.73% NextCure N/A -154.62% -100.19%

AquaBounty Technologies (AQB) Competitors

$1.05 +0.08 (+7.78%)

As of 10/9/2026 04:00 PM Eastern

Compare

AQB vs. AKTX, ESLA, MRKR, DYAI, and NXTC

Should you buy AquaBounty Technologies stock or one of its competitors? AquaBounty Technologies's main competitors and comparable companies include Akari Therapeutics (AKTX), Estrella Immunopharma (ESLA), Marker Therapeutics (MRKR), Dyadic International (DYAI), and NextCure (NXTC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AquaBounty Technologies compare to Akari Therapeutics?

AquaBounty Technologies (NASDAQ:AQB) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

In the previous week, Akari Therapeutics had 1 more articles in the media than AquaBounty Technologies. MarketBeat recorded 2 mentions for Akari Therapeutics and 1 mentions for AquaBounty Technologies. AquaBounty Technologies' average media sentiment score of 0.00 equaled Akari Therapeutics'average media sentiment score.

Company	Overall Sentiment
AquaBounty Technologies	Neutral
Akari Therapeutics	Neutral

Akari Therapeutics has a consensus target price of $32.33, suggesting a potential upside of 268.68%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akari Therapeutics is more favorable than AquaBounty Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Akari Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

8.9% of AquaBounty Technologies shares are owned by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are owned by institutional investors. 1.0% of AquaBounty Technologies shares are owned by insiders. Comparatively, 30.0% of Akari Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Akari Therapeutics has lower revenue, but higher earnings than AquaBounty Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AquaBounty Technologies	$2.47M	2.19	-$18.49M	-$0.82	N/A
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A

AquaBounty Technologies' return on equity of -147.07% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AquaBounty Technologies	N/A	-147.07%	-28.73%
Akari Therapeutics	N/A	-147.45%	-74.70%

AquaBounty Technologies has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

Summary

Akari Therapeutics beats AquaBounty Technologies on 7 of the 12 factors compared between the two stocks.

How does AquaBounty Technologies compare to Estrella Immunopharma?

Estrella Immunopharma (NASDAQ:ESLA) and AquaBounty Technologies (NASDAQ:AQB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Estrella Immunopharma has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, AquaBounty Technologies has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

Estrella Immunopharma has higher earnings, but lower revenue than AquaBounty Technologies. Estrella Immunopharma is trading at a lower price-to-earnings ratio than AquaBounty Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A
AquaBounty Technologies	$2.47M	2.19	-$18.49M	-$0.82	N/A

In the previous week, Estrella Immunopharma had 1 more articles in the media than AquaBounty Technologies. MarketBeat recorded 2 mentions for Estrella Immunopharma and 1 mentions for AquaBounty Technologies. Estrella Immunopharma's average media sentiment score of 0.67 beat AquaBounty Technologies' score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Estrella Immunopharma	Positive
AquaBounty Technologies	Neutral

0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are owned by institutional investors. 5.8% of Estrella Immunopharma shares are owned by insiders. Comparatively, 1.0% of AquaBounty Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Estrella Immunopharma's return on equity of 0.00% beat AquaBounty Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-328.72%
AquaBounty Technologies	N/A	-147.07%	-28.73%

Estrella Immunopharma presently has a consensus price target of $8.00, indicating a potential upside of 1,851.22%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than AquaBounty Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Estrella Immunopharma beats AquaBounty Technologies on 9 of the 14 factors compared between the two stocks.

How does AquaBounty Technologies compare to Marker Therapeutics?

Marker Therapeutics (NASDAQ:MRKR) and AquaBounty Technologies (NASDAQ:AQB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by insiders. Comparatively, 1.0% of AquaBounty Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Marker Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 929.23%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Marker Therapeutics is more favorable than AquaBounty Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Marker Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market. Comparatively, AquaBounty Technologies has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

Marker Therapeutics has higher revenue and earnings than AquaBounty Technologies. Marker Therapeutics is trading at a lower price-to-earnings ratio than AquaBounty Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	4.56	-$12.16M	-$0.41	N/A
AquaBounty Technologies	$2.47M	2.19	-$18.49M	-$0.82	N/A

In the previous week, Marker Therapeutics and Marker Therapeutics both had 1 articles in the media. Marker Therapeutics' average media sentiment score of 0.00 equaled AquaBounty Technologies'average media sentiment score.

Company	Overall Sentiment
Marker Therapeutics	Neutral
AquaBounty Technologies	Neutral

Marker Therapeutics' return on equity of -56.96% beat AquaBounty Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	N/A	-56.96%	-47.82%
AquaBounty Technologies	N/A	-147.07%	-28.73%

Summary

Marker Therapeutics beats AquaBounty Technologies on 11 of the 13 factors compared between the two stocks.

How does AquaBounty Technologies compare to Dyadic International?

AquaBounty Technologies (NASDAQ:AQB) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

8.9% of AquaBounty Technologies shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 1.0% of AquaBounty Technologies shares are owned by company insiders. Comparatively, 20.9% of Dyadic International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dyadic International has higher revenue and earnings than AquaBounty Technologies. Dyadic International is trading at a lower price-to-earnings ratio than AquaBounty Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AquaBounty Technologies	$2.47M	2.19	-$18.49M	-$0.82	N/A
Dyadic International	$3.09M	5.76	-$7.36M	-$0.23	N/A

In the previous week, Dyadic International had 3 more articles in the media than AquaBounty Technologies. MarketBeat recorded 4 mentions for Dyadic International and 1 mentions for AquaBounty Technologies. AquaBounty Technologies' average media sentiment score of 0.00 equaled Dyadic International'saverage media sentiment score.

Company	Overall Sentiment
AquaBounty Technologies	Neutral
Dyadic International	Neutral

AquaBounty Technologies has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market. Comparatively, Dyadic International has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 575.52%. Given Dyadic International's stronger consensus rating and higher probable upside, analysts plainly believe Dyadic International is more favorable than AquaBounty Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

AquaBounty Technologies has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. AquaBounty Technologies' return on equity of -147.07% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AquaBounty Technologies	N/A	-147.07%	-28.73%
Dyadic International	-201.43%	-2,920.31%	-84.77%

Summary

Dyadic International beats AquaBounty Technologies on 10 of the 15 factors compared between the two stocks.

How does AquaBounty Technologies compare to NextCure?

AquaBounty Technologies (NASDAQ:AQB) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

AquaBounty Technologies has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, NextCure has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

8.9% of AquaBounty Technologies shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 1.0% of AquaBounty Technologies shares are held by insiders. Comparatively, 11.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

AquaBounty Technologies has higher revenue and earnings than NextCure. AquaBounty Technologies is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AquaBounty Technologies	$2.47M	2.19	-$18.49M	-$0.82	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

AquaBounty Technologies' return on equity of -147.07% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AquaBounty Technologies	N/A	-147.07%	-28.73%
NextCure	N/A	-154.62%	-100.19%

NextCure has a consensus price target of $19.00, suggesting a potential upside of 164.62%. Given NextCure's stronger consensus rating and higher probable upside, analysts clearly believe NextCure is more favorable than AquaBounty Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, NextCure had 1 more articles in the media than AquaBounty Technologies. MarketBeat recorded 2 mentions for NextCure and 1 mentions for AquaBounty Technologies. AquaBounty Technologies' average media sentiment score of 0.00 equaled NextCure'saverage media sentiment score.

Company	Overall Sentiment
AquaBounty Technologies	Neutral
NextCure	Neutral

Summary

NextCure beats AquaBounty Technologies on 7 of the 13 factors compared between the two stocks.

Get AquaBounty Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AQB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AQB vs. The Competition

Export

Metric	AquaBounty Technologies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.40M	$3.93B	$7.26B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	-1.28	13.55	274.99	26.14
Price / Sales	2.19	1,209.42	582.85	87.95
Price / Cash	N/A	119.49	76.96	53.71
Price / Book	-2.14	17.17	11.22	6.33
Net Income	-$18.49M	-$22.69M	$3.50B	$382.15M
7 Day Performance	13.50%	-1.34%	-0.89%	-1.40%
1 Month Performance	-0.94%	-8.45%	-4.42%	-3.47%
1 Year Performance	-42.93%	14.02%	7.03%	1.18%

AquaBounty Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AQB AquaBounty Technologies	0.3314 of 5 stars	$1.05 +7.8%	N/A	-45.6%	$5.40M	$2.47M	N/A	3	Gap Up
AKTX Akari Therapeutics	2.9185 of 5 stars	$9.72 -0.9%	$32.33 +232.6%	-78.6%	$19.10M	N/A	N/A	5	Gap Up
ESLA Estrella Immunopharma	1.7319 of 5 stars	$0.46 +6.7%	$8.00 +1,638.8%	-66.7%	$18.77M	N/A	N/A	N/A	Positive News Gap Down
MRKR Marker Therapeutics	3.3574 of 5 stars	$1.10 -2.2%	$10.00 +809.1%	-7.5%	$18.76M	N/A	N/A	60	Positive News Gap Down
DYAI Dyadic International	3.0109 of 5 stars	$0.47 +0.2%	$3.00 +543.8%	-60.7%	$18.63M	$3.09M	N/A	5

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AQB) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AquaBounty Technologies (AQB) Competitors

AQB vs. AKTX, ESLA, MRKR, DYAI, and NXTC

How does AquaBounty Technologies compare to Akari Therapeutics?

Summary

How does AquaBounty Technologies compare to Estrella Immunopharma?

Summary

How does AquaBounty Technologies compare to Marker Therapeutics?

Summary

How does AquaBounty Technologies compare to Dyadic International?

Summary

How does AquaBounty Technologies compare to NextCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQB vs. The Competition

AquaBounty Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AquaBounty Technologies (AQB) Competitors

AQB vs. AKTX, ESLA, MRKR, DYAI, and NXTC

How does AquaBounty Technologies compare to Akari Therapeutics?

Does the media favor AQB or AKTX?

Do analysts prefer AQB or AKTX?

Do institutionals & insiders have more ownership in AQB or AKTX?

Which has preferable earnings and valuation, AQB or AKTX?

Is AQB or AKTX more profitable?

Which has more volatility and risk, AQB or AKTX?

Summary

How does AquaBounty Technologies compare to Estrella Immunopharma?

Which has more risk and volatility, ESLA or AQB?

Which has preferable valuation & earnings, ESLA or AQB?

Does the media favor ESLA or AQB?

Do insiders and institutionals believe in ESLA or AQB?

Is ESLA or AQB more profitable?

Do analysts rate ESLA or AQB?

Summary

How does AquaBounty Technologies compare to Marker Therapeutics?

Do institutionals and insiders have more ownership in MRKR or AQB?

Do analysts prefer MRKR or AQB?

Which has more risk & volatility, MRKR or AQB?

Which has preferable valuation and earnings, MRKR or AQB?

Does the media prefer MRKR or AQB?

Is MRKR or AQB more profitable?

Summary

How does AquaBounty Technologies compare to Dyadic International?

Do insiders and institutionals have more ownership in AQB or DYAI?

Which has better valuation & earnings, AQB or DYAI?

Does the media favor AQB or DYAI?

Which has more risk and volatility, AQB or DYAI?

Do analysts prefer AQB or DYAI?

Is AQB or DYAI more profitable?

Summary

How does AquaBounty Technologies compare to NextCure?

Which has more risk and volatility, AQB or NXTC?

Do institutionals & insiders believe in AQB or NXTC?

Which has better earnings and valuation, AQB or NXTC?

Is AQB or NXTC more profitable?

Do analysts rate AQB or NXTC?

Does the media prefer AQB or NXTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQB vs. The Competition

AquaBounty Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools